Product Updates and Looking Forward

 

The coronavirus pandemic has made this a challenging year for everyone. Our thoughts are with the many who have suffered, especially those with resulting life-threatening conditions, and those who have lost their jobs or their businesses. Cumberland is grateful to be part of an industry that is playing a key role in fighting back.

Mid-Year Check In and COVID-19 Updates

 

As the world continues to adapt to a new way of life due to the COVID-19 pandemic, Cumberland continues to take action to protect our employees, secure our supply chain and support the patients who can benefit from our medicines. Our office is open and we continue to operate our business while maintaining compliance with the many laws and regulations we fall under.

 

Caldolor®, RediTrex® and COVID-19 Updates

 

As the novel coronavirus has swept across the country, we have noted the profound changes affecting the economy, health care, employment and our daily lives.

2019 Review and Looking Forward

2019 Review and Looking Forward

Last year began with a strategic review of our brands, capabilities and international partners, which ultimately led to a restructured product portfolio, a host of new international partnerships and an expansion of our corporate, sales and medical teams.

New Ready-to-Use Caldolor is Designed to Help Address National Opioid Crisis.

 

We are very pleased to announce that the national launch of our FDA-approved Next Generation Caldolor product!

 

Cumberland Emerging Technologies Appoints a New Senior Executive

 

Cumberland Emerging Technologies, or CET, is a joint initiative between Cumberland Pharmaceuticals, Vanderbilt University, LaunchTN, and Winhealth Pharma Group. Its mission is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace.

 

Orphan Drug Grant Funding for New Clinical Program!

 

We’ve initiated the clinical development of ifetroban for the treatment of cardiomyopathy associated with Duchenne Muscular Dystrophy (DMD). Based on pre-clinical findings, the U.S. FDA has cleared our application to study ifetroban in DMD patients, 7 years of age and older.